Moderna (NASDAQ: MRNA) shares delivered top returns to investors in the earlier days of the pandemic. The stock soared more than 400% in 2020. This year, though, the stock is heading for a 30% loss, even though Moderna's coronavirus vaccine generates billions in revenue and profit.

Why? Investors are worried about revenue in a post-pandemic world.

Looking ahead to 2023, you might be wondering whether Moderna's best days are in the past -- or if this vaccine maker still presents an opportunity. Should you buy, sell, or hold Moderna in 2023? Let's find out.

Continue reading

Source Fool.com